JP2011525902A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525902A5
JP2011525902A5 JP2011515663A JP2011515663A JP2011525902A5 JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5 JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5
Authority
JP
Japan
Prior art keywords
pathogen
immune response
subject
composition
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011515663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525902A (ja
JP5712126B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2009/006260 external-priority patent/WO2009156852A1/en
Publication of JP2011525902A publication Critical patent/JP2011525902A/ja
Publication of JP2011525902A5 publication Critical patent/JP2011525902A5/ja
Application granted granted Critical
Publication of JP5712126B2 publication Critical patent/JP5712126B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011515663A 2008-06-25 2009-06-25 遅延型追加刺激免疫処置に対する迅速な応答 Expired - Fee Related JP5712126B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13314008P 2008-06-25 2008-06-25
US61/133,140 2008-06-25
PCT/IB2009/006260 WO2009156852A1 (en) 2008-06-25 2009-06-25 Rapid responses to delayed booster immunisations

Publications (3)

Publication Number Publication Date
JP2011525902A JP2011525902A (ja) 2011-09-29
JP2011525902A5 true JP2011525902A5 (OSRAM) 2012-08-09
JP5712126B2 JP5712126B2 (ja) 2015-05-07

Family

ID=41171092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515663A Expired - Fee Related JP5712126B2 (ja) 2008-06-25 2009-06-25 遅延型追加刺激免疫処置に対する迅速な応答

Country Status (5)

Country Link
US (1) US9421251B2 (OSRAM)
EP (1) EP2310045A1 (OSRAM)
JP (1) JP5712126B2 (OSRAM)
CA (1) CA2729248A1 (OSRAM)
WO (1) WO2009156852A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
PT3981427T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
EP2729165B1 (en) 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
WO2013006842A2 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20030072764A1 (en) * 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
TWI365074B (en) 2004-10-07 2012-06-01 Wyeth Corp Multivalent avian influenza vaccines
EP1814583A2 (en) * 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
DK1861120T3 (en) * 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
JP2009514840A (ja) * 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル インフルエンザワクチンによってプライム（ｐｒｉｍｉｎｇ）／ブースト（ｂｏｏｓｔｉｎｇ）するための投与経路
WO2007130330A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
US20080014217A1 (en) 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination

Similar Documents

Publication Publication Date Title
JP2011525902A5 (OSRAM)
Kim et al. Influenza vaccines: Past, present, and future
JP6308500B2 (ja) 強化された免疫賦活化剤
Alving et al. Adjuvants for human vaccines
Tregoning et al. Adjuvanted influenza vaccines
Levitz et al. Beyond empiricism: informing vaccine development through innate immunity research
Mori et al. The vaccine adjuvant alum inhibits IL‐12 by promoting PI 3 kinase signaling while chitosan does not inhibit IL‐12 and enhances T h1 and T h17 responses
Yusuf et al. Current prospects and future challenges for nasal vaccine delivery
Riese et al. Intranasal formulations: promising strategy to deliver vaccines
Skene et al. Saponin-adjuvanted particulate vaccines for clinical use
Smith et al. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines
Demirjian et al. Safety and efficacy of neonatal vaccination
CN109364244B (zh) 黏膜佐剂和递送系统
JP2003523310A (ja) 新規インフルエンザウイルスワクチン組成物
Dehghan et al. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants
TW200722101A (en) Novel composition
JP5712126B2 (ja) 遅延型追加刺激免疫処置に対する迅速な応答
Cheong et al. Epigallocatechin-3-gallate as a novel vaccine adjuvant
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
JP2015524802A5 (OSRAM)
JP2015529677A5 (OSRAM)
Krashias et al. Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer
de Veer et al. New developments in vaccine research—unveiling the secret of vaccine adjuvants
RU2017140856A (ru) Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
Davtyan et al. Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA-and recombinant protein-based Alzheimer's disease vaccines